학술논문
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755